Tag: Phaxiam
2023 – PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infectious endocarditis caused by Staphylococcus aureus
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned for the 4th…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus. Lyon…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
PHAXIAM Therapeutics announces a high level of performance of its two anti- Staphylococcus aureus on clinical strains Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test…
Phaxiam Therapeutics: high level of performance of both phages against clinical bacterial strains
By Alexandra Saintpierre Published on 09/10/2023 at 10:38 p.m. Photo credit © ChaunuPictures (Boursier.com) — Phaxiam Therapeutics announces…
PHAXIAM receives a notice of compliance from Nasdaq – 04/10/2023 at 22:05
Lyon (France) and Cambridge (MA, US), October 4, 2023, 10:05 p.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announces that it has received confirmation from Nasdaq that it…
PHAXIAM receives a notice of compliance from Nasdaq – 04/10/2023 at 22:05
PHAXIAM receives notice of compliance from Nasdaq Lyon (France) and Cambridge (MA, US), October 4, 2023, 10:05 p.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announces that it…
PHAXIAM Therapeutics and Vetophage announce strategic research collaboration – 10/03/2023 at 10:05 p.m.
PHAXIAM Therapeutics and V e tophage announce a strategic research collaboration Strategic research partnership between PHAXIAM Therapeutics and V e tophage, a biotechnology company specializing in veterinary phage therapy Pooling…
PHAXIAM Therapeutics and Vetophage announce strategic research collaboration – 10/03/2023 at 10:05 p.m.
Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specializing in veterinary phage therapy Pooling of expertise in the search for new phages and phage endolysins that can…
PHAXIAM takes stock of its activities and publishes its results for the first half of 2023 – 09/21/2023 at 10:05 p.m.
Creation of PHAXIAM Therapeutics with effect from June 23, 2023, in order to form a world leader in phage therapy targeting high value-added indications Development of an ambitious and value-creating…
Phaxiam Therapeutics up sharply after the launch of a program against antibiotic resistance – 09/19/2023 at 09:33
(AOF) – Phaxiam Therapeutics (+32.26% to 4.10 euros) posts one of the strongest increases in the SRD market after announcing the launch of a new preclinical development program targeting a…